The statement will aim to help clinicians navigate the increasingly complex options for management of hyperglycemia in type 2 diabetes, with particular emphasis on data published since 2014, including those suggesting cardiovascular benefit for the sodium-glucose cotransport-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.

Link to the ADA/EASD Guidance on Diabetes

No comments

The author does not allow comments to this entry